Neuronal ceroid lipofuscinosis

Neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease or CLN diseases, are a group of inherited neurodegenerative lysosomal storage disorders characterized by the progressive accumulation of autofluorescent lipopigments (ceroid and lipofuscin) in neurons and other cell types. These disorders primarily affect the central nervous system and represent the most common group of progressive neurodegenerative diseases in children, though adult-onset forms also exist. There are at least 13 recognized genetic forms (CLN1 through CLN14), each caused by mutations in different genes involved in lysosomal function or related cellular pathways. The hallmark clinical features of NCLs include progressive vision loss often leading to blindness, seizures (which may be difficult to control), progressive cognitive and motor decline, behavioral changes, and premature death. The age of onset, rate of progression, and specific symptom profile vary depending on the genetic subtype. Infantile forms (such as CLN1) tend to present between 6 months and 2 years of age with rapid neurodegeneration, while late-infantile forms (CLN2) typically present between ages 2 and 4. Juvenile-onset NCL (CLN3, classic Batten disease) usually manifests between ages 4 and 10, often beginning with vision loss. Adult-onset forms (CLN11, Kufs disease) may present with dementia and movement disorders without visual involvement. Diagnosis involves clinical evaluation, neuroimaging showing progressive cerebral and cerebellar atrophy, electroencephalography, enzyme activity assays, electron microscopy of tissue biopsies showing characteristic storage material ultrastructure (granular osmiophilic deposits, curvilinear profiles, or fingerprint profiles), and molecular genetic testing. Treatment has historically been limited to supportive and symptomatic care, including antiepileptic medications and physical, occupational, and speech therapies. However, cerliponase alfa (Brineura), an enzyme replacement therapy delivered intracerebroventricularly, was approved for CLN2 disease and represents a significant therapeutic advance. Gene therapy clinical trials are underway for several NCL subtypes, offering hope for future disease-modifying treatments.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Neuronal ceroid lipofuscinosis